Overview
Premature coronary artery disease (CAD) refers to atherosclerotic CAD occurring in individuals younger than the typical age of onset, often associated with modifiable risk factors and genetic predisposition 1.Diagnosis
Clinical presentation includes unstable angina, non-Q-wave myocardial infarction, and acute coronary syndrome 1.
Electrocardiogram (ECG) often shows ischemic changes.
Cardiac biomarkers (troponin) are elevated in myocardial infarction cases 1.
Coronary angiography may be necessary for definitive diagnosis and assessment of disease extent 1.Management
First-line treatment: Low-molecular-weight heparin (dalteparin 120 IU/kg twice daily initially, then 7500 IU once daily subcutaneously) in combination with aspirin 1.
Adjunctive therapy: Transition to oral anticoagulation or antiplatelet therapy post-acute phase as clinically indicated 1.Special Populations
No specific data provided in the abstracts regarding pregnancy, pediatrics, elderly, or comorbidities in the context of premature CAD management 1.Key Recommendations
Use low-molecular-weight heparin (dalteparin 7500 IU once daily subcutaneously) over placebo for prolonged treatment in patients with unstable coronary artery disease to potentially reduce adverse cardiovascular events (Evidence: Moderate) 1.
Combine low-molecular-weight heparin therapy with aspirin for optimal acute phase management of unstable coronary artery disease (Evidence: Strong) 1.
Consider transition to oral anticoagulation or antiplatelet therapy following the acute phase based on clinical judgment and patient-specific factors (Evidence: Expert opinion) 1.References
1 Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG et al.. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997. link